AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Can-Fite BioPharma's Namodenoson, in Phase 3 trials for liver cancer, shows dual benefits: anti-cancer and liver-protective effects via adiponectin. A patient remains cancer-free for over 8 years. Data to be presented at ASCO 2025.

OSCO's 2024 In-Person Fall Conference, a Best of ASCO® event, will showcase key oncology research and strategies from ASCO®'s 2024 Annual Meeting, aimed at updating healthcare professionals in oncology.

Telehealth adoption surged during COVID-19, enabling cancer patients, especially those immunosuppressed, to receive care without clinic visits. Post-pandemic, it remains vital for those with transportation issues or living far. Licensing restrictions, temporarily lifted, now limit cross-state telehealth, affecting continuity of care. Advocating for policy changes to support rare disease patients and addressing technology access disparities are next steps.

FDA approved subcutaneous nivolumab for all solid tumor indications previously approved for nivolumab, supported by CheckMate-67T trial data showing noninferiority to intravenous administration.

FDA approved Akebia Therapeutics’ vadadustat for anemia in CKD patients on dialysis. GLP-1RA and SGLT2i combination reduces CKD by 33%. Mediterranean and DASH diets lower CVD risk in T1D patients. Semaglutide shows benefits for CKD and CVD in T2D patients. GLP-1s improve CVD outcomes and weight loss in breast cancer patients.

Multiple myeloma (MM) is a treatable but incurable hematologic malignancy. Advances in treatment, including proteasome inhibitors and immunomodulatory agents, have improved survival rates. Current therapies focus on combination regimens, with ongoing research into bispecific antibodies and CAR T-cell therapies for relapsed/refractory MM.

A pilot study by Jessica Bauman, MD, introduced a longitudinal, integrated palliative care rotation for hematology/oncology fellows, aiming to improve their palliative care skills. The study showed significant improvements in fellows' knowledge, preparedness, and confidence in providing palliative care, with high acceptability and value ratings from participants.

The FDA approved lifileucel for melanoma treatment, showing promise in overcoming resistance to checkpoint inhibitors. Novel therapies and combinations, including lifileucel with pembrolizumab and IBI363, are under investigation. A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab, reduced disease recurrence risk. The 21st Annual International Symposium on Melanoma will discuss these advancements and more.

Edward S. Kim, MD, pivoted from engineering to oncology after his brother's death, driven by a desire to improve healthcare access. His career highlights include landmark research on biomarkers for lung cancer and efforts to diversify clinical trials. Kim balances his professional achievements with family life, including viral TikTok fame for attending a Taylor Swift concert with his daughter.